ProQR Therapeutics N.V.
General ticker "PRQR" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $196.7M (TTM average)
ProQR Therapeutics N.V. follows the US Stock Market performance with the rate: 1.2%.
Estimated limits based on current volatility of 2.3%: low 1.82$, high 1.91$
Factors to consider:
- Total employees count: 187 (+12.7%) as of 2025
- Price in estimated range
- Earnings for 6 months up through Q2 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [1.42$, 3.23$]
- 2026-12-31 to 2027-12-31 estimated range: [1.35$, 3.10$]
Financial Metrics affecting the PRQR estimates:
- Positive: with PPE of -4.6 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Positive: Interest expense per share per price, % of 0.46 <= 0.75
- Negative: negative Industry operating cash flow (median)
- Positive: -1.23 < Investing cash flow per share per price, % of -0.54
- Positive: Inventory ratio change, % of -2.85 <= -1.30
- Negative: 0 < Industry inventory ratio change (median), % of 0
- Negative: negative Net income
Short-term PRQR quotes
Long-term PRQR plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | €6.51MM | €18.91MM | €15.28MM |
| Operating Expenses | €38.37MM | €49.38MM | €57.43MM |
| Operating Income | €-31.86MM | €-30.47MM | €-42.15MM |
| Non-Operating Income | €4.05MM | €2.51MM | €1.65MM |
| Interest Expense | €1.20MM | €1.08MM | €0.87MM |
| R&D Expense | €25.15MM | €36.36MM | €40.72MM |
| Income(Loss) | €-27.81MM | €-27.96MM | €-40.50MM |
| Taxes | €-0.08MM | €-0.20MM | €0.02MM |
| Net Income(Loss)* | €-28.12MM | €-27.76MM | €-40.52MM |
| Stockholders Equity | €45.72MM | €91.70MM | €57.99MM |
| Assets | €152.31MM | €173.92MM | €132.43MM |
| Operating Cash Flow | €21.55MM | €-36.39MM | €-52.79MM |
| Capital expenditure | €1.37MM | €1.42MM | €1.02MM |
| Investing Cash Flow | €4.28MM | €-4.07MM | €-1.02MM |
| Financing Cash Flow | €-2.27MM | €70.28MM | €-1.84MM |
| Earnings Per Share** | €-0.35 | €-0.34 | €-0.38 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.